Co-treatment with resveratrol and rosuvastatin in streptozotocin-induced DN re-established kidney Nrf2 levels and reduced TGFβ1 and fibronectin gene expression as well as urinary TGFβ1 levels [199]. The gene discussed is NFE2L2; the disease is liver dysplastic nodule.